Jurriaan Brouwer-Visser
Overview
Explore the profile of Jurriaan Brouwer-Visser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brouwer-Visser J, Cheng W, Bauer-Mehren A, Maisel D, Lechner K, Andersson E, et al.
Cancer Epidemiol Biomarkers Prev
. 2017 Nov;
27(1):103-112.
PMID: 29133367
The tumor microenvironment is an important factor in cancer immunotherapy response. To further understand how a tumor affects the local immune system, we analyzed immune gene expression differences between matching...
12.
Merritt M, Strickler H, Einstein M, Yang H, Sherman M, Wentzensen N, et al.
Cancer Causes Control
. 2016 Apr;
27(6):737-48.
PMID: 27125830
Purpose: Experimental and observational data link insulin, insulin-like growth factor (IGF), and estrogens to endometrial tumorigenesis. However, there are limited data regarding insulin/IGF and sex hormone axes protein and gene...
13.
Mi S, Lin M, Brouwer-Visser J, Heim J, Smotkin D, Hebert T, et al.
Clin Cancer Res
. 2016 Apr;
22(18):4676-86.
PMID: 27121792
Purpose: Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less than 2 years due to high relapse rates...
14.
Brouwer-Visser J, Huang G
Cytokine Growth Factor Rev
. 2015 Feb;
26(3):371-7.
PMID: 25704323
Upregulation of IGF2 occurs in both childhood and adult malignancies. Its overexpression is associated with resistance to chemotherapy and worse prognosis. IGF2 promoter usage is developmentally regulated; however, malignant tissues...
15.
Leegant A, Zuckerwise L, Downing K, Brouwer-Visser J, Zhu C, Cossio M, et al.
Female Pelvic Med Reconstr Surg
. 2014 Sep;
21(1):53-8.
PMID: 25185601
Objectives: This study was undertaken to evaluate the expression of transforming growth factor β1 (TGF-β1) and matrix metalloproteinase 9 (MMP-9), key regulators of the extracellular matrix composition, in the uterosacral...
16.
Brouwer-Visser J, Lee J, McCullagh K, Cossio M, Wang Y, Huang G
PLoS One
. 2014 Jun;
9(6):e100165.
PMID: 24932685
Drug resistance is an obstacle to the effective treatment of ovarian cancer. We and others have shown that the insulin-like growth factor (IGF) signaling pathway is a novel potential target...
17.
Chao S, Lin J, Brouwer-Visser J, Smith 3rd A, Horwitz S, McDaid H
Proc Natl Acad Sci U S A
. 2010 Dec;
108(1):391-6.
PMID: 21173253
Discodermolide is a microtubule-stabilizing agent that induces accelerated cell senescence. A discodermolide-resistant cell line, AD32, was generated from the human lung cancer cell line A549. We hypothesize that the major...
18.
Lizama C, Rojas-Benitez D, Antonelli M, Ludwig A, Bustamante-Marin X, Brouwer-Visser J, et al.
Reproduction
. 2010 May;
140(2):305-17.
PMID: 20501791
The pathways leading to male germ cell apoptosis in vivo are poorly understood, but are highly relevant for the comprehension of sperm production regulation by the testis. In this work,...
19.
Huang G, Brouwer-Visser J, Ramirez M, Kim C, Hebert T, Lin J, et al.
Clin Cancer Res
. 2010 Apr;
16(11):2999-3010.
PMID: 20404007
Purpose: This study was undertaken to examine the role of the insulin-like growth factor (IGF) signaling pathway in the response of ovarian cancer cells to Taxol and to evaluate the...